Fig. 4From: Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATEPer-cycle comparison between the expected absorbed dose (ADE) in Gy (when based on a fixed-AD per AA scheme) and the delivered absorbed dose (ADD) for all six-patients (P1-P6) for a the tumour and b the kidneysBack to article page